Cipla, a prominent pharmaceutical company, revealed in a stock exchange filing on April 5 that its Board of Directors is scheduled to convene on May 10 to discuss and approve standalone and consolidated audited financial results for Quarter 4 and the fiscal year ending on March 31, 2024. Additionally, the company announced that the Board will deliberate on recommending a final dividend for the financial year 2023-24, if deemed appropriate.
Furthermore, Cipla stated that it would release the audited financial results for Quarter 4 of the fiscal year 2023-24 on May 10.
Cipla has maintained its tradition of consistent dividend payouts over several years, demonstrating its commitment to rewarding shareholders. For the fiscal year ending in March 2023, Cipla declared an equity dividend of 425%, amounting to Rs 8.5 per share.
In the preceding fiscal year 2021-22, Cipla declared an equity dividend of 250%, equivalent to Rs 5 per equity share, with a face value of Rs 2 per equity share.
On April 5, Cipla made headlines as the US Food and Drug Administration (USFDA) issued a Form 483 with six inspectional observations for the company’s manufacturing facility in Patalganga, Maharashtra.
In the quarter ending December 2023, Cipla reported a consolidated net profit of Rs 1,068.4 crore, marking a 32.25% increase compared to the same period the previous year.
During the trading session on April 5, the company’s stock settled at Rs 1449.40 apiece at the NSE, representing a 0.70% decrease (or Rs 10.15) from the previous day’s close.
